GHK-Cu Dosing & Reconstitution Guide

GHK-Cu can be administered through various routes, including subcutaneous, topical (in the form of creams or serums), and intradermal methods, such as microneedling. Research indicates that subcutaneous administration may be performed once daily, while topical applications can range from once to twice daily. The suggested dose range for subcutaneous use is between 50 to 200 mcg per day, whereas topical formulations typically comprise 1–4% concentration applied to the targeted area. The duration of treatment cycles may vary, with 8 to 16 weeks often recommended for skin rejuvenation and anti-aging purposes, while ongoing applications are common in wound healing scenarios. Consistency in timing is emphasized, particularly for topical applications, which are ideally performed following skin cleansing to enhance absorption.

For research applications, GHK-Cu is typically supplied in a lyophilized form, with a standard vial size of 50 mg. To achieve the desired concentration for use, it is recommended to reconstitute the peptide with 2.5 mL of sterile water. This process results in a concentration of 20 mg/mL. Proper reconstitution is critical to ensure the stability and efficacy of the peptide in experimental settings. Researchers should exercise caution during this process to minimize the risk of contamination and ensure accurate dosing in subsequent applications.

In preclinical studies, a titration schedule for GHK-Cu has been observed to facilitate gradual acclimatization to the peptide. Initial dosing often begins at 50 mcg subcutaneously daily during the first two weeks. This is followed by an increase to 100 mcg daily over the next two weeks. After this initial period, dosing may escalate to a range of 100 to 200 mcg daily, depending on the specific research goals and outcomes being monitored. This structured approach allows for careful observation of effects and minimizes the potential for adverse reactions, contributing to a more thorough understanding of the compound's impact.

The pharmacokinetics of GHK-Cu reveal distinct profiles depending on the route of administration. Topical application may yield observable effects over days to weeks, while subcutaneous injections typically result in a more rapid onset, with peak plasma concentrations achieved approximately 1 to 2 hours post-administration. Notably, GHK-Cu exhibits a short plasma half-life; however, its copper-peptide complex is known to provide sustained activity within tissues. Research suggests that visible improvements in skin condition may take 4 to 8 weeks to manifest, with hair growth effects potentially requiring 8 to 12 weeks. These timelines underscore the importance of patience and consistent application in research endeavors.

The storage conditions for GHK-Cu are crucial for maintaining its integrity and effectiveness in research applications. When in its lyophilized state, the peptide should be stored at −20 °C (−4 °F). Once reconstituted, GHK-Cu must be kept at a temperature range of 2 to 8 °C (35.6 to 46.4 °F) to preserve its activity. The shelf life of the reconstituted solution is limited to 28 days, necessitating careful planning for usage within this timeframe to ensure optimal results in experimental contexts.

For subcutaneous administration of GHK-Cu, common injection sites include the abdomen and areas adjacent to the targeted treatment region. This localized approach is intended to enhance the peptide's effects on specific tissues. Research indicates that selecting appropriate injection sites can influence the absorption and efficacy of the peptide, thereby optimizing its potential benefits in tissue repair and regeneration. Careful consideration of anatomical landmarks and patient-specific factors may further inform site selection in research applications.

The safety profile of GHK-Cu has been well-documented, with a history of minimal side effects observed over decades of both cosmetic and clinical applications (PMID: 29986520). Topical formulations are generally well-tolerated, with mild skin irritation reported infrequently and typically confined to individuals with particularly sensitive skin. Injectable forms may induce mild reactions at the injection site, including localized irritation, lightheadedness, nausea, or flu-like symptoms. To mitigate local irritation, it is advisable to rotate injection sites.

In terms of contraindications, individuals with copper sensitivity, Wilson disease, or Menkes disease—conditions associated with abnormal copper metabolism—should avoid GHK-Cu. Additionally, the peptide should not be administered to individuals with active skin infections at the application site. The safety of GHK-Cu during pregnancy and breastfeeding has not been established, warranting caution in these populations.